TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Definite MS diagnosis according to McDonald's criteria;~* Relapsing clinical course, with or without progression;~* Expanded Disability Status Scale \[EDSS\] less or equal to 5.5 (ambulatory);~* Stable dose of IFN-β for at least 26 weeks prior to the screening visit;~* No onset of MS relapse in the preceding 60 days prior to randomization;~* Clinically stable for 4 weeks prior to randomization.~Exclusion Criteria:~* Other chronic disease of the immune system, liver function impairment or chronic pancreatic disease;~* Pregnant or nursing woman;~* Alcohol or drug abuse;~* Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;~* Human immunodeficiency virus \[HIV\] positive status;~* Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide 7 mg + IFN-β (Type: EXPERIMENTAL): Teriflunomide 7 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
- Teriflunomide 14 mg + IFN-β (Type: EXPERIMENTAL): Teriflunomide 14 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
- Placebo + IFN-β (Type: PLACEBO_COMPARATOR): Placebo (for Teriflunomide) once daily concomitantly with Interferon-β (IFN-β) for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates in the Neonatal Intensive Care or Special Care Nursery who have been fed orally or by feeding tube.~* Term or post-term infants with a body weight of \>800 gms.~* Pre-term infants with a corrected age of less than 44 weeks.~* Clinically-evident GERD (feeding intolerance, regurgitation, wheezing or stridor with feedings)~* At least 7 days post-surgery without anticipated need for surgery during study~* No significant laboratory abnormalities~Exclusion Criteria:~* Unstable, clinically significant disease or abnormality~* Congenital anomaly of the upper gastrointestinal tract~* Clinical evidence of acute sepsis~* Cystic fibrosis~* Medical condition requiring subject to not be fed by mouth/gastric tube

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Lansoprazole 0.5 mg/kg QD (Type: EXPERIMENTAL): None
- Lansoprazole 1.0 mg/kg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nexium Dyspepsia/AST

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least 3 months of symptoms of pain or burning centered in the upper abdomen prior to enrollment.~* Helicobacter pylori test performed at enrollment must be negative (Helicobacter pylori is a bacterial infection of the stomach).~Exclusion Criteria:~* Patients with symptoms of other gastrointestinal diseases, such as Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD).~* Helicobacter pylori eradication treatment during the last 12 months prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Consistency Lots Vaccine Study (V260-009)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants~Exclusion Criteria:~* History of abdominal disorders from a birth defect, intussusception, or abdominal surgery~* Known or suspected problems with the immune system~* Fever at time of immunization~* Prior administration of a rotavirus vaccine~* History of known prior rotavirus disease, chronic diarrhea, or failure to thrive.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- RotaTeq™ Lot 1 (Type: EXPERIMENTAL): \~8.81 X 10\^7 IU/Dose of RotaTeq™
- RotaTeq™ Lot 2 (Type: EXPERIMENTAL): \~8.01 X 10\^7 IU/Dose of RotaTeq™
- RotaTeq™ Lot 3 (Type: EXPERIMENTAL): \~6.91 X 10\^7 IU/Dose of RotaTeq™
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simethicone and N-acetylcysteine in Upper Endoscopy - Prospective Double-blinded Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* consecutive series of patients scheduled for upper gastrointestinal endoscopy~* signed informed consent~Exclusion Criteria:~* sedation~* previous total gastrectomy~* known neoplasia or stenosis~* therapeutic or urgent procedures~* allergies to simethicone or N-acetylcysteine

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Group A - 100mL of water by mouth, 15 to 30 minutes before endoscopy
- Simethicone (Type: ACTIVE_COMPARATOR): Group B - 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
- Simethicone plus N-acetylcysteine (Type: ACTIVE_COMPARATOR): Group C - 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CD22-positive, B-cell NHL which has progressed after 1 or 2 prior therapies.~* Patients who have progressed after at least 1 prior chemotherapy regimen for indolent lymphoma, or 1/ 2 chemotherapy regimens, which include anthracylin or anthraquinon for aggressive lymphoma.~* Eastern Cooperative Oncology Group (ECOG) performance status: 0/ 1.~Exclusion Criteria:~* Patients must not have received monoclonal antibodies or radioimmunoconjugates within 3 months before first dose of test article.~* Patients must not have received bilateral pelvic irradiation.~* Patients must not have received chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents within 4 weeks before first dose of test article.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-chip Meta-analysis of Parkinson's Disease for Clinical Validation of Small Samples of Key Genes in Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* PD group：~  * Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria~ * Newly diagnosed primary PD patients, diagnosed within 3-6 months~ * Informed consent to the study~ * Age \> 18 older~* Non-PD group:~  * Age, gender-matched PD group~ * Non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history~ * Informed consent to the study~ * Age \> 18 older~Exclusion Criteria:~* Severe craniocerebral trauma patients~* Disturbance of consciousness~* Severe organic diseases, cerebral hemorrhage, cerebral thrombosis, severe coronary heart disease and lung disease, severe liver and kidney dysfunction, severe diabetes, severe hearing And visual impairment~* History of severe brain tumors, encephalitis or brain surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Parkinson's disease group (Type: None): 1. Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;~2. Newly diagnosed primary PD patients, diagnosed within 3-6 months;~3. informed consent to the study;~4. age \> 18 older.
- Non-parkinson group (Type: None): Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age \> 18 older.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 and above years of age inclusive, at the time of signing the informed consent.~* Subjects with suspected ILD listed for TBCB for clinical reasons following review by the ILD services at University College London Hospitals (UCLH) in whom diagnosis has remained unclear following radiological and clinical assessment.~* A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied, may be included only if the investigator in consultation with the Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.~* Male or Female.~* Capable of giving signed informed consent which includes compliance with the requirements and restrictions.~Exclusion Criteria:~* Subjects who have a known drug allergy or other contra-indication to ipratropium bromide.~* Known hypersensitivity to atropine or ipratropium bromide or any other known drug allergies that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.~* As a result of the medical history, physical examination or screening investigations, the physician responsible considers the subject unfit for the study.~* The subject is unable or unwilling to perform study assessments and procedures correctly.~* Subjects with a recognized co-existing respiratory disorder (other than ILD) that in the opinion of the investigator would confound the study outcomes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with suspected fibrotic ILD (Type: None): Eligible subjects will receive nebulized ipratropium bromide 500 mcg for 10 minutes. The subjects will be sedated for bronchoscopic procedure as per routine practice for subjects having bronchoscopy. Cryobiopsy samples for this study will be taken after samples required for diagnosis has been taken and it is safe to do so. One to three endobronchial forceps biopsy samples will be taken from up to 5 subjects to allow comparison of proximal and distal drug distribution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AQI and Childhood Asthma: an Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child Inclusion criteria includes:~  1. physician diagnosis of persistent asthma- either mild, moderate, or severe;~ 2. family home internet access and/or smartphone access + willingness to download AirNow app on phone;~ 3. age 8-17 years.~Parent/guardian inclusion: parent or guardian of the child participant, of whom has met inclusion criteria.~Exclusion Criteria:~* Child exclusion criteria includes:~  1. diagnosis of other chronic respiratory disease (e.g. cystic fibrosis, bronchopulmonary dysplasia, etc)~ 2. immunodeficiency- acquired or congenital~ 3. neuromuscular disease~ 4. disability affecting ambulation~ 5. cyanotic congenital heart disease~ 6. only 1 child per household eligible~ 7. no plans to leave Pittsburgh area in next 6 months~Parental/guardian exclusion criteria: none.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Routine Care (Type: ACTIVE_COMPARATOR): None
- AQI Intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Advanced or metastatic malignant disease originating from solid tumors~* Adequate recovery from previous therapy or intervention; at least 21 days since major surgery or prior radiation therapy~* Measurable or evaluable disease~Exclusion criteria:~* Women of childbearing potential (WOCBP) who are breastfeeding, pregnant, or unwilling or unable to use acceptable contraception during the study and for at least 12 weeks after the last on-study dose of cetuximab~* Men unwilling to use acceptable contraception during the study if engaged in sexual relations with a WOCBP~* Symptomatic brain metastasis~* History of myocardial infarction 6 months or less prior to study entry, of severe congestive heart failure, of uncontrolled angina, or of uncontrolled arrhythmias~* Clinically relevant abnormality on screening electrocardiogram (ECG), preventing an accurate measurement of the QT interval~* Congenital long QT syndrome~* History of risk factors for ventricular tachycardia or Torsades de pointes or history of fainting, unexplained loss of consciousness, or convulsions~* Prolonged QTc interval on screening ECG (greater than 470 msec) using Fridericia's correction formula~* Heart rate slower than 50 bpm or faster than 100 bpm at rest during screening ECG measurements~* Implantable pacemaker or automatic implantable cardioverter defibrillator~* Sustained supine systolic blood pressure higher than 150 mmHg or lower than 90 mmHg or a diastolic blood pressure lower than 45 mmHg or higher than 95 mmHg at screening~* Known history of arterial thrombotic events within 6 months prior to study initiation~* Known history of significant peripheral artery disease~* Current participation in a clinical trial with another investigational new drug or device~* Receipt of an investigational new drug or device within 21 days prior to enrollment in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ginsenoside-Rd for Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* between 18 to 75 years~* the first episode~* from onset to admission within 72 hours~* NIHSS scores:5\~22~Exclusion Criteria:~* had other intracranial pathologies (e.g., tumor, infection)~* had a neurologic or psychiatric disease~* had a coexisting condition that limited their life expectancy~* had significant drug or alcohol misuse~* had high-grade carotid artery stenosis for which surgery was planned~* were pregnant or nursing~* participated in a clinical trial with an investigational drug or device within the past 3 months~* were unlikely to be available for follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ginsenoside-Rd 10mg (Type: EXPERIMENTAL): both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.
- placebo (Type: PLACEBO_COMPARATOR): 2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.
- ginsenoside-Rd 20mg (Type: EXPERIMENTAL): 2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of previously treated advanced chronic lymphocytic leukemia (CLL)~  * Fludarabine-refractory disease~ * Requires treatment~PATIENT CHARACTERISTICS:~* Life expectancy more than 6 months~* ECOG 0-2~* No severe organ dysfunction~* No other concomitant or previous neoplasms~* No autoimmune hemolytic anemia or thrombocytopenia~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Up to 5 prior chemotherapy regimens allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* primary diagnosis of ADHD combined subtype or the predominantly hyperactive-impulsive subtype based on a psychiatric evaluation that reviews DSM-IV criteria~* functioning at age appropriate levels intellectually~* blood pressure measurements within the 95th percentile for their gender, height and age~* ECG results are within the normal range~Exclusion Criteria:~* comorbid psychiatric diagnosis (such as psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder) or other symptomatic manifestations~* history of seizures (exclusive of febrile seizure), a tic disorder, or a family history of Tourette's disorder~* weighs less than 55 lbs (25 kg)or is significantly overweight or obese~* clinically significant ECG abnormality~* documented allergy or intolerance to amphetamines

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic renal anemia;~* hemodialysis or peritoneal dialysis, with same mode of dialysis for \>=3 months before and throughout screening period;~* stable maintenance epoetin alfa therapy for past 2 months.~Exclusion Criteria:~* transfusion of red blood cells during previous 2 months;~* poorly controlled hypertension requiring interruption of epoetin alfa in past 6 months;~* acute or chronic bleeding during previous 2 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C.E.R.A (Type: EXPERIMENTAL): Participants with chronic renal anaemia who were on dialysis and previously treated with intravenous (IV) or subcutaneous (SC) epoetin alfa, epoetin beta or darbepoetin alfa received monthly treatment with Continuous Erythropoietin Receptor Activator (C.E.R.A.) (methoxy polyethylene glycol-epoetin beta \[Mircera\]). The initial dose of C.E.R.A. was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA); 120, 200, or 360 micrograms (mcg) C.E.R.A., IV or SC, every 4 weeks for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete